Collegium Pharmaceutical (STU:354) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:354 Collegium Pharmaceutical Inc STU:354
72 GF Score
Price €20.20
GF Value €41.07
! 2 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

STU:354
72GF Score
Collegium Pharmaceutical Inc STU:354
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Collegium Pharmaceutical (STU:354) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of €20.20 is trading 50.8% below its estimated GF Value™ of €41.07.

Key valuation signals for STU:354:

  • Interest Expense (Positive):
  • GF Value™: €41.07 vs. price of €20.20 (50.8% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the STU:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Collegium Pharmaceutical Business Description

Other Exchanges COLL:USA
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
72GF Score

Get the complete analysis for STU:354

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.20
Price
€41.07
GF Value